MCID: LRY018
MIFTS: 44

Laryngeal Squamous Cell Carcinoma

Categories: Cancer diseases, Oral diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Laryngeal Squamous Cell Carcinoma

MalaCards integrated aliases for Laryngeal Squamous Cell Carcinoma:

Name: Laryngeal Squamous Cell Carcinoma 12 54 15 17
Epidermoid Carcinoma of the Larynx 12
Squamous Cell Carcinoma of Larynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2876
NCIt 50 C4044
SNOMED-CT 67 707358000
UMLS 71 C0280324

Summaries for Laryngeal Squamous Cell Carcinoma

Disease Ontology : 12 A laryngeal carcinoma that has material basis in squamous cells.

MalaCards based summary : Laryngeal Squamous Cell Carcinoma, also known as epidermoid carcinoma of the larynx, is related to larynx cancer and squamous cell papilloma. An important gene associated with Laryngeal Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Docetaxel and Pembrolizumab have been mentioned in the context of this disorder. Affiliated tissues include lymph node, thyroid and endothelial, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Laryngeal Squamous Cell Carcinoma

Diseases related to Laryngeal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 326)
# Related Disease Score Top Affiliating Genes
1 larynx cancer 32.6 TP53 NME1 MIR21 EGFR CDKN2A CCND1
2 squamous cell papilloma 31.7 TP53 CDKN2A
3 papilloma 31.6 VEGFA TP53 EGFR CDKN2A CCND1
4 squamous cell carcinoma 31.2 VEGFA TP53 NME1 NEAT1 MALAT1 HOTAIR
5 in situ carcinoma 31.0 TP53 EGFR CDKN2A CDH1 CCND1
6 human papillomavirus infectious disease 31.0 TP53 CDKN2A
7 b-cell lymphoma 30.9 TP53 MIR21 MALAT1 HOTAIR CDKN2A CCND1
8 suppression of tumorigenicity 12 30.8 VEGFA TP53 EGFR CDKN2A CDH1 AURKA
9 oropharynx cancer 30.8 TP53 EGFR CDKN2A CDH1 CCND1
10 basaloid squamous cell carcinoma 30.7 TP53 EGFR CDKN2A
11 verrucous carcinoma 30.7 TP53 EGFR CDKN2A CCND1
12 laryngeal disease 30.7 TP53 MIR21 CDKN2A CCND1
13 small cell carcinoma 30.6 TP53 EGFR CDKN2A
14 suppressor of tumorigenicity 3 30.6 TP53 CDKN2A
15 squamous cell carcinoma, head and neck 30.6 VEGFA TP53 MIR21 HOTAIR H19 EGFR
16 adenocarcinoma 30.6 VEGFA TP53 MALAT1 H19 EGFR CDKN2A
17 retinitis pigmentosa 11 30.5 TP53 NEAT1 HOTAIR EGFR CDKN2A
18 thyroid cancer, nonmedullary, 1 30.5 NEAT1 MALAT1 HOTAIR H19
19 adenoid cystic carcinoma 30.5 VEGFA TP53 EGFR CDKN2A CDH1 CCND1
20 intrahepatic cholangiocarcinoma 30.4 TP53 EGFR CDH1 CCND1 CCAT1
21 retinoblastoma 30.4 TP53 MALAT1 HOTAIR CDKN2A CCND1 CCAT1
22 gastrointestinal stromal tumor 30.4 VEGFA TP53 HOTAIR EGFR CDKN2A CDH1
23 leukemia, chronic myeloid 30.3 TP53 NME1 HOTAIR H19 EGFR
24 thyroid carcinoma 30.2 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
25 lung cancer susceptibility 3 29.9 VEGFA TP53 MIR21 MALAT1 HOTAIR H19
26 cholangiocarcinoma 29.8 VEGFA TP53 NEAT1 MIR21 MALAT1 H19
27 renal cell carcinoma, nonpapillary 29.6 VEGFA TP53 NME1 MIR21 MALAT1 HOTAIR
28 melanoma 29.5 VEGFA TP53 NME1 MALAT1 HOTAIR H19
29 bladder cancer 29.4 VEGFA TP53 MIR21 MALAT1 HOTAIR H19
30 oral squamous cell carcinoma 29.3 VEGFA TP53 NEAT1 MIR21 MALAT1 HOTAIR
31 nasopharyngeal carcinoma 28.9 VEGFA TP53 NME1 NEAT1 MIR21 MALAT1
32 osteogenic sarcoma 28.8 TP53 NEAT1 MALAT1 HOXA11-AS HOTAIR H19
33 lung cancer 28.1 VEGFA TP53 NME1 NEAT1 MIR21 MALAT1
34 leukoplakia 10.6
35 esophageal leukoplakia 10.5 TP53 CCND1
36 pancreatic foamy gland adenocarcinoma 10.5 TP53 CCND1
37 pediatric angiosarcoma 10.5 VEGFA TP53
38 vulvar intraepithelial neoplasia 10.5 TP53 CDKN2A CDH1
39 mammary analogue secretory carcinoma 10.5 TP53 EGFR CCND1
40 bowenoid papulosis 10.5 CDKN2A CCND1
41 soft tissue sarcoma 10.5 VEGFA TP53 EGFR
42 cystitis 10.5 VEGFA TP53 CDH1
43 synchronous bilateral breast carcinoma 10.5 TP53 EGFR CCND1
44 nodular malignant melanoma 10.5 TP53 CDKN2A CCND1
45 malignant peritoneal mesothelioma 10.5 EGFR CDKN2A
46 supraglottis cancer 10.5 TP53 EGFR CDKN2A
47 childhood malignant schwannoma 10.5 TP53 CCND1 AURKA
48 adult malignant schwannoma 10.5 TP53 CDKN2A AURKA
49 primary peritoneal carcinoma 10.5 VEGFA TP53 EGFR
50 sarcomatoid transitional cell carcinoma 10.5 TP53 CDH1

Graphical network of the top 20 diseases related to Laryngeal Squamous Cell Carcinoma:



Diseases related to Laryngeal Squamous Cell Carcinoma

Symptoms & Phenotypes for Laryngeal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.66 AURKA EGFR
2 Decreased viability GR00055-A-2 9.66 AURKA EGFR
3 Decreased viability GR00221-A-1 9.66 AURKA CDH1 CDKN2A EGFR NME1
4 Decreased viability GR00221-A-2 9.66 AURKA NME1
5 Decreased viability GR00221-A-3 9.66 CDKN2A
6 Decreased viability GR00221-A-4 9.66 AURKA CDKN2A EGFR
7 Decreased viability GR00231-A 9.66 AURKA
8 Decreased viability GR00249-S 9.66 AURKA NME1
9 Decreased viability GR00301-A 9.66 CDH1
10 Decreased viability GR00402-S-2 9.66 AURKA CDH1 NME1

MGI Mouse Phenotypes related to Laryngeal Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 AURKA CCND1 CDH1 CDKN2A EGFR NME1

Drugs & Therapeutics for Laryngeal Squamous Cell Carcinoma

Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
2
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
3
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
4
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
5
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
6
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
7
Trioxsalen Approved Phase 2 3902-71-4 5585
8
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
9
leucovorin Approved Phase 2 58-05-9 6006
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
11 Antimitotic Agents Phase 2
12 Antineoplastic Agents, Immunological Phase 1, Phase 2
13 Tubulin Modulators Phase 2
14 Immunoglobulins Phase 1, Phase 2
15 Antibodies Phase 1, Phase 2
16 Albumin-Bound Paclitaxel Phase 2
17 Antimetabolites Phase 2
18 Dihematoporphyrin Ether Phase 2
19 Dermatologic Agents Phase 2
20 Hematoporphyrin Derivative Phase 2
21 Photosensitizing Agents Phase 2
22 Ether Phase 2
23 Nutrients Phase 2
24 Protective Agents Phase 2
25 Micronutrients Phase 2
26 Vitamin B Complex Phase 2
27 Trace Elements Phase 2
28 Astragalus Phase 2
29 Vitamins Phase 2
30 Folate Phase 2
31 Vitamin B9 Phase 2
32 Antidotes Phase 2
33
Mitoguazone Investigational 459-86-9
34 Cola

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP) Recruiting NCT04030455 Phase 2 Carboplatin;Cisplatin;Docetaxel
2 A Phase I/II Study of Chemo Radiation Plus the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma Active, not recruiting NCT02759575 Phase 1, Phase 2 Pembrolizumab;Cisplatin
3 A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy Active, not recruiting NCT03067610 Phase 2 chemotherapy
4 Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II Terminated NCT02068157 Phase 2 Photodynamic Therapy;Porfimer Sodium
5 A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Terminated NCT01720563 Phase 2 Astragalus polysaccharides 500 mg;Placebo
6 Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
7 Validation of a Screening Tool in Geriatric Oncology Completed NCT00963911
8 Hyperfractionation and Accelerated Fractionation in Comparison With Conventional Fractionation in Definitive Radiotherapy of Squamous Cell Carcinoma of Larynx, Oropharynx and Hypopharynx Completed NCT00291434

Search NIH Clinical Center for Laryngeal Squamous Cell Carcinoma

Genetic Tests for Laryngeal Squamous Cell Carcinoma

Anatomical Context for Laryngeal Squamous Cell Carcinoma

MalaCards organs/tissues related to Laryngeal Squamous Cell Carcinoma:

40
Lymph Node, Thyroid, Endothelial, Neutrophil, T Cells, Breast, Skin

Publications for Laryngeal Squamous Cell Carcinoma

Articles related to Laryngeal Squamous Cell Carcinoma:

(show top 50) (show all 2145)
# Title Authors PMID Year
1
GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. 54 61
19922706 2010
2
Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. 61 54
19741544 2010
3
EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. 54 61
19789511 2009
4
Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. 61 54
19669840 2009
5
Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. 54 61
19375219 2009
6
[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. 61 54
19813623 2009
7
[The expressions and correlation of AQP1 and VEGF in laryngeal squamous cell carcinoma]. 61 54
19670620 2009
8
Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. 61 54
19148533 2009
9
[The expression of Galectin-3 and VEGF in laryngeal squamous cell carcinoma]. 61 54
19452726 2009
10
p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. 61 54
18607952 2009
11
Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. 54 61
19183379 2009
12
Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. 61 54
18998509 2008
13
[hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice]. 54 61
19173799 2008
14
[Expression of angiopoietin-1,2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma]. 61 54
19086654 2008
15
[Effect of CDK2 on proliferation in laryngeal squamous cell carcinoma]. 54 61
19166026 2008
16
Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma. 61 54
18602381 2008
17
[Study of the lymph node micrometastasis in patients with supraglottic carcinoma]. 54 61
19166031 2008
18
[Detection of Skp2 mRNA gene expression using fluorogenic probe quantitative RT-PCR method in laryngeal squamous cell carcinoma]. 54 61
18800682 2008
19
Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. 54 61
18509272 2008
20
Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. 54 61
17592663 2008
21
Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. 54 61
18357366 2008
22
[Expression of cyclin G1 in laryngeal squamous cell carcinoma and its clinicopathologic significance]. 61 54
18788592 2008
23
[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. 61 54
18476631 2008
24
Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. 61 54
18787961 2008
25
Possible prognostic role of p53 expression in laryngeal squamous cell carcinoma of non-smokers, non-alcoholic patients. 61 54
18607961 2008
26
Expression of PTEN protein in patients with laryngeal squamous cell carcinoma. 54 61
17475427 2007
27
[Effects of HPV 16-E6/E7 oncogene on expression of vascular endothelial growth factor and matrix metalloproteinase 9 in human laryngeal squamous cell carcinoma cell line]. 61 54
18307884 2007
28
Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. 54 61
17974987 2007
29
[Expression and clinical significance of Endostatin, vascular endothelial growth factor and fibroblast growth factor basic-2 in laryngeal carcinoma]. 54 61
18051571 2007
30
Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. 61 54
17712678 2007
31
[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. 61 54
17634026 2007
32
[Clinical significance and expression of FLIP and PTEN protein in laryngeal squamous cell carcinoma]. 61 54
17441421 2007
33
Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC). 54 61
17328665 2007
34
The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. 54 61
17264532 2007
35
[Expression and clinical significance of matrix metalloproteinase-2 in laryngeal squamous cell carcinoma]. 61 54
17357514 2006
36
5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. 54 61
17207318 2006
37
[Expression of telomerase reverse transcriptase and its relationship with expression of c-myc in laryngeal squamous cell carcinomas]. 54 61
17219990 2006
38
Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. 54 61
16938565 2006
39
Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. 61 54
17094406 2006
40
Immunohistochemical estimation of cell cycle phase in laryngeal neoplasia. 61 54
16832409 2006
41
[Construction of recombinant adenovirus vector carrying cell cycle controlling gene-p14ARF]. 61 54
16845966 2006
42
[The investigation of STK15 gene amplification and overexpression in laryngeal squamous cell carcinoma]. 61 54
16767676 2006
43
[The relationship between hypermethylation of the PTEN promoter and laryngeal squamous cell carcinoma]. 61 54
16739377 2006
44
[The clinical significance of the expression of p63 gene in laryngeal squamous cell carcinoma]. 54 61
16646404 2006
45
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance. 54 61
16711020 2006
46
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. 54 61
15965904 2006
47
[Inhibitory effect of silencing hTERT gene by short hairpin RNA on growth of human laryngeal squamous cell carcinoma xenograft in nude mice]. 54 61
16405742 2006
48
[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]. 54 61
16763427 2006
49
Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma. 54 61
16711019 2006
50
Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. 54 61
16265652 2006

Variations for Laryngeal Squamous Cell Carcinoma

Expression for Laryngeal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Laryngeal Squamous Cell Carcinoma.

Pathways for Laryngeal Squamous Cell Carcinoma

Pathways related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 VEGFA TP53 EGFR CDKN2A CDH1 CCND1
2 12.64 VEGFA TP53 EGFR CDKN2A CDH1 CCND1
3
Show member pathways
12.61 TP53 EGFR CDKN2A CDH1 CCND1
4
Show member pathways
12.52 TP53 EGFR CDKN2A CDH1 CCND1
5 12.23 VEGFA TP53 MIR21 EGFR CDKN2A CCND1
6 12.22 TP53 CDKN2A CDH1 CCND1
7 12.08 VEGFA TP53 MIR21 EGFR CCND1
8 11.94 VEGFA TP53 EGFR CDH1 CCND1
9 11.75 TP53 EGFR CDKN2A CCND1
10 11.62 VEGFA TP53 EGFR CDH1 CCND1 AURKA
11
Show member pathways
11.56 VEGFA EGFR CCND1
12 11.42 VEGFA TP53 CDKN2A
13 11.38 VEGFA TP53 CCND1
14 11.16 TP53 EGFR CDKN2A CCND1
15 11.15 NME1 CDH1 CCND1
16 10.96 VEGFA TP53 EGFR CDKN2A CDH1 CCND1
17 10.65 TP53 HOTAIR

GO Terms for Laryngeal Squamous Cell Carcinoma

Biological processes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.96 VEGFA TP53 MIR21 EGFR AURKA
2 positive regulation of gene expression GO:0010628 9.92 VEGFA TP53 MIR21 CDKN2B-AS1 CDKN2A
3 positive regulation of cell migration GO:0030335 9.84 VEGFA MIR21 EGFR CDKN2B-AS1
4 positive regulation of protein phosphorylation GO:0001934 9.78 VEGFA MIR21 EGFR CCND1
5 positive regulation of inflammatory response GO:0050729 9.74 NEAT1 MIR21 EGFR
6 positive regulation of protein kinase B signaling GO:0051897 9.73 VEGFA MIR21 H19 EGFR
7 cellular response to drug GO:0035690 9.67 TP53 NME1 EGFR
8 positive regulation of epithelial cell proliferation GO:0050679 9.63 VEGFA NME1 EGFR
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.55 TP53 EGFR
10 lactation GO:0007595 9.54 VEGFA NME1 CCND1
11 mitotic G1 DNA damage checkpoint GO:0031571 9.51 TP53 CCND1
12 cellular response to virus GO:0098586 9.5 RRP1B MIR21 H19
13 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.4 VEGFA TP53
14 negative regulation of superoxide dismutase activity GO:1901670 9.26 MIR21 H19
15 negative regulation of gene expression GO:0010629 9.17 VEGFA TP53 NME1 MIR21 HOXA11-AS CDKN2B-AS1
16 response to UV-A GO:0070141 9.16 EGFR CCND1
17 liver regeneration GO:0097421 9.13 EGFR CCND1 AURKA

Molecular functions related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.35 TP53 EGFR CDKN2A CCND1 AURKA
2 MDM2/MDM4 family protein binding GO:0097371 8.62 TP53 CDKN2A

Sources for Laryngeal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....